Literature DB >> 2689425

In-vivo and in-vitro interference of antibiotics with antigen-specific antibody responses: effect of josamycin.

M L Villa1, F Valenti, F Scaglione, M Falchi, F Fraschini.   

Abstract

The effects of josamycin on the antigen-specific primary antibody responses of human peripheral blood cells have been studied by the method of haemolytic colonies in soft agar. The tests were performed before and after the oral administration of 1 g of josamycin or by adding the drug directly to cultures of cells from untreated donors. The results demonstrate that josamycin, added in vitro or administered in vivo significantly depresses the primary antibody responses. The mechanism by which josamycin exerts its activity on antibody production has been partially elucidated. The immunodepression depends on the stimulation of hydrogen peroxide production by monocytes and requires the actual presence of josamycin during the immune response. The stimulation of the respiratory burst of the phagocytic cell is a common feature of macrolide antibiotics and suggests the need for more extensive clinical and preclinical trials on antibacterial antibiotics that alter the human immune responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689425     DOI: 10.1093/jac/24.5.765

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

2.  In vivo administration of azithromycin affects lymphocyte activity in vitro.

Authors:  J Tomazic; V Kotnik; B Wraber
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

3.  Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial.

Authors:  Gholamreza Mokhtari; Mojtaba Teimoori
Journal:  Trials       Date:  2018-06-28       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.